The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...
FDA approves esketamine nasal spray as a standalone treatment for adults with treatment-resistant depression, offering rapid ...
The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...
People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.
“Hopefully, this approval by the FDA shows that there is sufficient evidence for esketamine working that providers and patients and their families will be comfortable and more confident that in ...
The results, which come on the heels of the FDA’s approval of J&J’s esketamine nasal spray Spravato as a monotherapy for ...
On Tuesday, the US Food and Drug Administration (FDA) approved Johnson & Johnson's hallucinogenic drug esketamine (brand name ...
A ketamine-based nasal spray is officially the first and only standalone therapy available for treatment-resistant depression ...
CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...
Because it is still awaiting approval, Medicare does not typically cover the use of ketamine infusion for treating mental ...